Endometrial hyperplasia (EH), especially in the presence of atypia, has a strong tendency to the development of endometrial carcinoma. In this respect, hysterectomy is a preferred treatment for atypical EH. However, for young patient who desire to preserve their fertility or for patients not selected for surgery, conservative treatments using progestin are widely accepted as a treatment option [1] .
group (53/53) including 6 atypical hyperplasia were obtained complete remission. The response rate of continuous oral progestin was 96% (46/48) and cyclic oral progestin was only 69% (36/52).
In this issue of the Journal of Gynecologic Oncology, Shan et al. [10] reports a pilot study that compared the efficacy of metformin plus MA with MA alone in treating endometrial atypical EH patients. To date, only a few case report about combined metformin with high dose progestin or oral contraceptives therapy for progestin resistant atypical EH have been reported [11, 12] . Even though 75% of response rate in metformin plus oral progestin group is relatively unsatisfactory compared to reported result in treatment of atypical EH with LNG-IUS, the present study is meaningful for being the first clinical trial that has evaluated the efficacy of metformin plus oral progestin for treatment of atypical EH.
Obesity, metabolic syndrome, polycystic ovarian syndrome (PCOS), insulin resistance and type II diabetes are significant risk factors of EH. Furthermore, chronic hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit progestogen therapy [14] . Metformin, insulin sensitizer, decreases insulin resistance by the inhibition of hepatic gluconeogenesis. Metformin not only lowers insulin levels and can also provide benefits by decreasing body weight, which diminishes the peripheral conversion of androgen. In addition, a low body index is related to a high resolution rate in EH patients with progestin treatment [15] . Therefore, metformin may be proposed as an alternative agent for treatment of EH, especially for patients who have progestin resistance or other metabolic disorders. Then, what is the best way to treat atypical EH to alternate oral progestin or in case of treatment failure in oral progestin therapy-LNG-IUS or oral progestin As we know, LNG-IUS have high intrauterine, but low systemic levels of progestin. Therefore, it can be more effective in endometrium without incurring side effects such as breast tenderness, mood changes and weight gain. Moreover, it is con venient compared to daily dosing with oral progestin. Mean while, as mentioned above, insulin resistance and meta bolic syndrome can be related with progestin resistance. In the present study, patients who met at least on metabolic syndrome criterion were enrolled. Relatively low response rate could be explained in this way. In these patients with progestin resistant or metabolic disorder such as PCOS, obesity, adding metformin can be helpful. Recently, as a conservative treatment of EH, the study about LNG-IUS with metformin is ongoing along with LNG-IUS or oral progestin plus metformin [16] .
Although this study is a pilot study and has limitations to conclude effectiveness and safety of medical treatment using metformin for atypical EH, the significance of metformin can be suggested as combined therapy with progesterone in patients with expected progestin resistance. Further investigation and large prospective clinical trial in this area is needed.
